Oral submucous fibrosis (OSF) is a chronic insidious disease associated with betel quid chewing and clinically characterized by progressive fibrosis of oral mucosa and limited mouth opening. It is not only limited to Asian countries but also spreading all over the world due to the immigrant population and has become a global health problem (Aziz, 2010;Farrand et al., 2001). OSF manifests as limited mouth opening, burning sensation, palpable fibrous bands, loss of elasticity of mucosa, blanching of mucosa, restricted tongue movements, and shrunken or bending of uvula (Gondivkar, Bhowate, Gadbail, Gaikwad, et al., 2018). Apart from these, loss of taste sensation, hearing, and speech difficulties with differing degrees of severity have also been reported in the literature (Devi et al., 2015). The WHO Collaborating Center for Oral Cancer has classified OSF as an oral potentially malignant disorder (OPMD) (Warnakulasuriya et al., 2007), and this is re-affirmed in their recent report (Warnakulasuriya et al., 2020). A recent meta-analysis on OSF confirms a malignant transformation rate of 4.2% (95% CI: 2.7%-5.6%; Kujan et al., 2020).Although many therapeutic interventions have been tried in past, none of them proved to be a superior option for the holistic management of OSF symptoms (Chole et al., 2012). Therefore, at present,